Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06346392 · ClinicalTrials.gov registry record · Phase 3
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
A Phase 3 study of Gastric Cancer and Gastroesophageal-junction Cancer, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 572
- Enrollment target
- 20
- Study locations
NCT06346392 is a Phase 3 study of Gastric Cancer and Gastroesophageal-junction Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 572 participants, above the 316-participant average among 153 other Gastric Cancer trials with a reported enrollment target (81% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT06346392, a Phase 3 study of Gastric Cancer and Gastroesophageal-junction Cancer, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 572 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Paclitaxel
- DRUG AZD0901
- DRUG Ramucirumab+ paclitaxel
Study Locations (20)
California
- Research Site - Duarte
- Research Site - Fullerton
- Research Site - Irvine
- Research Site - Los Angeles
- Research Site - Los Angeles
- Research Site - Newport Beach
- Research Site - Santa Rosa
Florida
- Research Site - Fleming Island
- Research Site - Hollywood
- Research Site - Orlando
Alabama
- Research Site - Birmingham
- Research Site - Mobile
Georgia
- Research Site - Atlanta
- Research Site - Marietta
Arizona
- Research Site - Tucson
District of Columbia
- Research Site - Washington D.C.
Hawaii
- Research Site - Honolulu
Idaho
- Research Site - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 572 participants |
| Start Date | 2024-03-04 |
| Est. Completion | 2026-09-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06346392
The ClinicalTrials.gov registry entry for NCT06346392 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 572 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 316-participant average among 153 other Gastric Cancer trials with a reported enrollment target (81% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 4 interventions - of which Docetaxel is the first listed.
NCT06346392 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT06346392 about?
NCT06346392 is a clinical study titled "AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2". The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.
What is the current status of trial NCT06346392?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 572 participants. The study started on 2024-03-04. Estimated completion is 2026-09-14.
What conditions does trial NCT06346392 study?
This clinical trial studies the following conditions: Gastric Cancer, Gastroesophageal-junction Cancer.
What interventions are being tested in trial NCT06346392?
The interventions under investigation include: Docetaxel (DRUG), Paclitaxel (DRUG), AZD0901 (DRUG), Ramucirumab+ paclitaxel (DRUG).
Who is sponsoring clinical trial NCT06346392?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06346392 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
RECRUITING · Phase 3
-
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
RECRUITING · Phase 3
-
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
RECRUITING · Phase 3
-
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
ACTIVE NOT RECRUITING · Phase 3
-
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
ACTIVE NOT RECRUITING · Phase 3
-
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.